| Prev Close | 41,63 |
| Open | 41,58 |
| Day Low/High | 41,58 / 44,78 |
| 52 Wk Low/High | 1,50 / 23,40 |
| Volume | 682.64K |
Celldex Therapeutics, Inc. (CLDX)
44,52
2,89
6,94
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 45.57B |
| Market Cap | 1.98B |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Market Wrap: Stocks Retreat on China Devaluation
However, utilities and some technology names bucked the trend.
Biotech Stocks at a Crossroad
Own them, or take something off the table?
Many Ways to Win
Try to find bullish charts that don't all look the same.
No Reason to Jump Long
I'm content to sit in cash and wait for a trigger.
A Brick Wall for Bulls
The S&P is putting up strong resistance that has withstood several attacks today.
Fitz Bits: Careful With Those Highfliers
In other words, don't overstay your welcome.
Opportune Selloffs
This action makes it a good time to add to two quality names.
Setting Up a Pair of Plays
Qualcomm seems to be breaking out of a bullish flag, and Celldex has a fantastic chart.
Some Weekend Folding Money
I'm content to head into the weekend with my short-term book mostly on the cash side.
5 Dumbest Things on Wall Street
Blackberry's Flying Circus, Foolish Filmmaker, Celldex Shenanigans, Benmosche's Big Mouth and Chrysler's Conundrum highlight Gregg Greenberg's list of dumb things on Wall Street this week.
Biotech Breakouts
Favorable charts for Celldex, Repligen and Arrowhead Research.
Off the Charts
Maintain a long-side bias until composure changes.
Off the Charts
The S&P is in an uptrend but the market is in digestion mode.
Feels Like a Bear Market
The best thing to do is get out of the way and let it play out.
The Action Has Shifted
And the close put an exclamation point on it.
Stock-Picking Wins the Day
There's still speculative interest out there.
Bulls Deserve Respect
It really is amazing how this market keeps roaring back.
Too Much Chop
I'm eager to enter new trades but leery of forcing things.
Momentum Is Lacking
Action is a mixed bag so far.
The Next Big Thing In Biotech: Celldex
Adam Feuerstein, Sr. Columnist for TheStreet, says Celldex Therapeutics is the next big thing in biotech.
Next Big Thing in Biotech: Cancer Drug Stocks
Senior columnist Adam Feuerstein explains why cancer drug stocks are the next big thing in biotech.
The Next Big Thing in Biotech: BIO CEO Conference
Adam Feuerstein, senior columnist, explains why the BIO CEO Conference is the next big thing in biotech.
